<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176409</url>
  </required_header>
  <id_info>
    <org_study_id>VALIANT-001</org_study_id>
    <nct_id>NCT01176409</nct_id>
  </id_info>
  <brief_title>Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?</brief_title>
  <acronym>VALIANT Pilot</acronym>
  <official_title>VALacyclovir for Inflammation AttenuatioN Trial Pilot (VALIANT Pilot)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the levels of immune and inflammatory markers among
      HIV-1, HSV-2 co-infected adults achieving plasma HIV RNA suppression to &lt;50 copies/mL,
      between those randomized to valacyclovir and placebo, over a twelve-week intervention period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Highly active antiretroviral therapy (HAART) has dramatically reduced HIV-1 infection (herein
      referred to as 'HIV') related morbidity and mortality, transforming an invariably fatal
      disease into a manageable, chronic condition. Yet even HAART-treated HIV infection is
      characterized by chronic systemic inflammation and immune activation. This systemic
      inflammatory response is composed of multiple components, and can be quantified by measuring
      markers of immune activation, inflammatory cytokines, acute phase reactants, endothelial
      activation markers, and markers of microbial translocation. This inflammation is clinically
      relevant, as it may contribute directly to HIV disease progression and non-AIDS related
      morbidity and mortality in HIV-infected patients. Because this inflammation persists even in
      the context of suppressive HAART, albeit at modestly decreased levels, adjunctive therapeutic
      strategies to attenuate this persistent inflammatory response are therefore needed. Herpes
      simplex virus type 2 is a common, clinically important co-infection seen in individuals
      living with HIV infection, and may contribute to this ongoing inflammation. This pilot trial
      will investigate whether short-term valacyclovir for HSV-2 suppression can decrease systemic
      inflammation in HAART-treated, HIV-1, HSV-2 co-infected individuals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage activated CD8+ T-cells</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of CD8+ T-cells co-expressing CD38 and HLA-DR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>12 weeks</time_frame>
    <description>IL-6, hsCRP, sICAM-1, LPS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 cell count</measure>
    <time_frame>12 weeks</time_frame>
    <description>CD4 cell count (absolute and percentage)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic blips</measure>
    <time_frame>12 weeks</time_frame>
    <description>Plasma HIV RNA level &gt;50 copies/mL but &lt;1000 copies/mL, followed by a repeat plasma HIV RNA level &lt;50 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug-related adverse events</measure>
    <time_frame>18 weeks</time_frame>
    <description>Adverse events (AEs) are defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study medication. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not it is related to the medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HSV reactivations</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical reactivations of herpes simplex virus. Simultaneous reactivations at more than one anatomic site will be counted as a single reactivation event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acyclovir-resistant HSV</measure>
    <time_frame>18 weeks</time_frame>
    <description>Clinical reactivations of herpes simplex virus that are microbiologically confirmed to be caused by acyclovir-resistant virus.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>Herpes Simplex</condition>
  <arm_group>
    <arm_group_label>High dose valacyclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valacyclovir 1g po BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose valacyclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valacyclovir 500mg po BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inert placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <description>Valacyclovir will be used at two different dosages (1g po BID and 500mg po BID) to be used for 12 weeks. Supplied as 500mg caplets.</description>
    <arm_group_label>High dose valacyclovir</arm_group_label>
    <arm_group_label>Low dose valacyclovir</arm_group_label>
    <other_name>Apo-Valacycyclovir</other_name>
    <other_name>Valtrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, supplied as caplets identical in appearance, odour and taste to valacyclovir 500mg caplets.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult (aged 18 years or older)

          -  documented HIV-1 infection (determined by EIA and Western blot)

          -  documented HSV-2 seropositivity (determined by ELISA during screening)

          -  no use of chronic anti-HSV therapy for the past 6 months, and not anticipated to
             require chronic anti-HSV therapy during the study

          -  sustained plasma HIV RNA&lt;50 copies/mL on HAART for at least 12 months

          -  no active opportunistic infection for at least 12 months

        Exclusion Criteria:

          -  hepatitis C co-infection

          -  hepatitis B co-infection

          -  pregnancy or actively planning to become pregnant

          -  receiving chemotherapy, chronic steroid therapy or other immunomodulatory medications
             (e.g. interferon, azathioprine, methotrexate, TNF-alpha antagonists, etc.)

          -  Estimated creatinine clearance &lt;30 mL/min

          -  Other medical condition likely to cause death within 24 months

          -  Enrolled in any other interventional clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darrell HS Tan, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharon L Walmsley, MD FRCPC MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto General Hospital, University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23946220</url>
    <description>Study Results</description>
  </link>
  <results_reference>
    <citation>Yi TJ, Walmsley S, Szadkowski L, Raboud J, Rajwans N, Shannon B, Kumar S, Kain KC, Kaul R, Tan DH. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy. Clin Infect Dis. 2013 Nov;57(9):1331-8. doi: 10.1093/cid/cit539. Epub 2013 Aug 14.</citation>
    <PMID>23946220</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2010</study_first_submitted>
  <study_first_submitted_qc>August 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2010</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

